Natick, MA – According to filings with the U.S. Securities and Exchange Commission, Garuda Therapeutics is raising $71,790,005.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Dhvanit Shah played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Garuda Therapeutics
Garuda Therapeutics seeks to create a world which eliminates the dependency on donor or patient cells for blood stem cell transplants. Our platform technology for generating off-the-shelf, self-renewing blood stem cells is poised to provide patients with rapid and broad access to consistent, durable, HLA-compatible transgene-free blood stem cell therapies. Like bone marrow transplants, our technology could provide potentially curative therapies for more than 70 diseases.

To learn more about Garuda Therapeutics, visit http://garudatx.com/

Contact:
Dhvanit Shah, Chief Executive Officer
978-335-2781
https://www.linkedin.com/in/dhvanitshah/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved